Belite Bio, Inc (BLTE) Stock Forecast and Price Target (2026)

The average target of $210.50 sits well above the $160.67 price, +31.0%. The median is $200.50, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $185.00 to $266.00. That gap is 38% of the average target, which counts as moderate disagreement. That is a fairly typical spread: enough agreement that the average means something, enough disagreement that it should not be treated as precise.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the BLTE is it a buy page.

In the last six months there have been 3 raises and 1 cut among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

Of the analysts with a published rating, 8 say buy, 0 say hold, and 0 say sell, so 100% carry a buy. That mix has been broadly steady over the last three months.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

In short: the drivers cited most often are The FDA decision on tinlarebant in Stargardt disease, A small, genetically findable patient population, PHOENIX in geographic atrophy is the larger and less certain prize. The risk cited most often against it is this is a one-molecule company, so an FDA setback on tinlarebant would take most of the equity story with it.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the BLTE is it a buy page. This page deliberately stops at the numbers.